Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Consultation record

Submissions noted, no amendment — page 2

The submission raises a point the Institute accepts but that does not require a change to the draft, most often because the draft already states it elsewhere. The location is given in the response.

Submissions

127 documents · page 2 of 5

Table 1. Submissions with this disposition, on this page.

ReferenceConsultationRespondentPoint raised
DRAFT-PEOPLE-REGIS/002Draft policy on the register of members and reviewersDr Zofia Petrossian industryThe disclosure requirements exceed those of comparable bodies
DRAFT-CORRECTIONS-/011Draft corrections and versioning policyRosalind PetrossianA sortable table implies a comparison the underlying data do not support
DRAFT-STABILITY-ST/006Draft standard: freeze–thaw and in-use stability assessment of…Dr Ngozi ZetterlundA superseded version should remain reachable from the version that replaced it
DRAFT-INDICATION-S/003Draft indication set and anchor outcomesDr Ludmila Castellanos-ReidA superseded version should remain reachable from the version that replaced it
DRAFT-INDICATION-S/005Draft indication set and anchor outcomesDr Liesbeth Delacroix-NjokuDeclared interests should appear on the document rather than on a separate page
DRAFT-INDICATION-S/008Draft indication set and anchor outcomesDr Quentin Whitmarsh-ObiA sortable table implies a comparison the underlying data do not support
DRAFT-MASH-SYNTHES/003Draft synthesis: incretin receptor agonists for metabolic…Dr Mordecai Bellingham-OjoA sortable table implies a comparison the underlying data do not support
DRAFT-ADOLESCENT-S/006Draft synthesis: incretin receptor agonists in adolescentsDr Thaddeus Isaksen-BalogunA sortable table implies a comparison the underlying data do not support
DRAFT-ADOLESCENT-S/005Draft synthesis: incretin receptor agonists in adolescentsDr Melisande Kirkpatrick-OlaDeclared interests should appear on the document rather than on a separate page
DRAFT-ANALYTICAL-S/014Draft analytical review: surveys of unregulated peptide supplyDr Séverine Oduya-KaltenbrunnerA sortable table implies a comparison the underlying data do not support
DRAFT-REGISTRY-STR/004Draft structure of the document registryDr Mordecai Glendinning-UcheA superseded version should remain reachable from the version that replaced it
DRAFT-TOOLS-DISCLA/015Draft terms for the Institute’s calculatorsDr Rukayat Zaleski-MbekiThe Institute publishes no telephone number and no messaging channel
DRAFT-TOOLS-DISCLA/010Draft terms for the Institute’s calculatorsMs Rhiannon Okoye-VandergraafA sortable table implies a comparison the underlying data do not support
DRAFT-TOOLS-DISCLA/012Draft terms for the Institute’s calculatorsDr Xenia Uttridge industryThe disclosure requirements exceed those of comparable bodies
DRAFT-TOOLS-DISCLA/005Draft terms for the Institute’s calculatorsLeonhard AchterbergDeclared interests should appear on the document rather than on a separate page
DRAFT-TOOLS-DISCLA/011Draft terms for the Institute’s calculatorsDr Nadezhda LavrentievA superseded version should remain reachable from the version that replaced it
DRAFT-ORFORGLIPRON/005Draft monograph: orforglipronDr Melisande Kirkpatrick-OlaDeclared interests should appear on the document rather than on a separate page
DRAFT-METHODOLOGY-/019Draft methodology document, version 4Dr Hyacinth Oyelaran-SteenA superseded version should remain reachable from the version that replaced it
DRAFT-METHODOLOGY-/003Draft methodology document, version 4Dr Theodora XimenesA superseded version should remain reachable from the version that replaced it
DRAFT-METHODOLOGY-/007Draft methodology document, version 4Dr Marisol Dunmore-EkpoA sortable table implies a comparison the underlying data do not support
DRAFT-METHODOLOGY-/011Draft methodology document, version 4Rosalind PetrossianDeclared interests should appear on the document rather than on a separate page
DRAFT-SUPPLIERS-CO/006Draft supplier comparison tableDr Prosper VercingetorixDeclared interests should appear on the document rather than on a separate page
DRAFT-SUPPLIERS-CO/009Draft supplier comparison tableDr Ngozi ZetterlundA superseded version should remain reachable from the version that replaced it
DRAFT-RETATRUTIDE-/005Draft monograph: retatrutideDr Lorcan Zaleski-MbekiDeclared interests should appear on the document rather than on a separate page
DRAFT-RETATRUTIDE-/004Draft monograph: retatrutideYusuf Whitmarsh-ObiGuidance on lyophilised storage is missing
DRAFT-MELANOCORTIN/007Draft scoping review: melanocortin receptor agonistsDr Rukayat Zaleski-MbekiBaseline imbalance in a small contributing trial is not remarked on
DRAFT-SEARCH-STRAT/004Draft search-strategy template for the synthesis seriesZdenka XimenesThe document should describe how an assessment becomes a decision
DRAFT-SEARCH-STRAT/009Draft search-strategy template for the synthesis seriesIgnatius ErlingssonDeclared interests should appear on the document rather than on a separate page
DRAFT-SEARCH-STRAT/015Draft search-strategy template for the synthesis seriesDr Zdenka Nyquist-ObioraA superseded version should remain reachable from the version that replaced it
DRAFT-PRINT-AND-AR/002Draft print and archival format for Institute documentsDr Leonhard QuennevilleDeclared interests should appear on the document rather than on a separate page

page 2 of 5

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.